Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream). In addition, its devices targeting cardiology include Semi-compliant PTCA Balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), and Coronary CTO Antegrade Micro-Catheter (Vericor-14); devices targeting nephrology include Paclitaxel Coated High-Pressure Balloon (ACOART AVENS) and AV Scoring Balloon (Peridge); devices targeting neurology comprise Intracranial PTA Balloon (NEO-Skater); and devices targeting andrology include AcoArt Orchid & Dhalia and AcoArt Tulip & Litos. Further, the company trades procedural medical devices. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc. Address: Building No. 1, Beijing, China